⌘K
Molbio Diagnostics is a medical technology company focused on infectious disease diagnostics. It emphasizes R&D and has a global presence with its 'Truenat' platform. The IPO consists of a fresh issue and a significant Offer for Sale, aiming to fund capital expenditure and for general corporate purposes.
Deterministic verdict 'Neutral': listing=73/Apply, short=64/Neutral Positive, long=68/Apply; overall=65.5; confidence=100.0/100 | computed financials: fin=80, growth=100, D/E=0.36 (70% math / 30% model) | market signals: alignment=20 (OFS 78.7%), anchor quality=85 (marquee 53.8%), GMP trend=fading, overhang=82 (-4.5 pts short-term) | demand profile: reservation weights QIB/NII/Ret 29%/21%/50%, QIB effective demand=53.25x, institutional contribution=76%, breadth=0.65 | unlocks: anchor unlock ~15.0% of issue at T+30d, ~15.0% at T+90d; OFS-heavy issue (78.7% exit paper) | rule: mixed signals -> Neutral. | Analyst notes: The 'Strong Apply' verdict is driven by Molbio Diagnostics' impressive financial growth, with revenue CAGR of 31.96% and PAT CAGR of 40.7% over FY24-FY26, coupled with healthy margins and strong return ratios. The company operates in a high-growth medical technology sector, supported by robust R&D and a global presence. Market sentiment is exceptionally strong, evidenced by an overall subscription of 70.27x (QIB at 186.39x) and a healthy GMP of 19.08%. While the valuation is not cheap, it is justified by its growth profile relative to peers. However, the auditor's disclaimer on internal financial controls for FY23 and FY24, along with high customer and supplier concentration, are significant governance and operational risks that necessitate careful monitoring. Despite these risks, the overwhelming positive factors outweigh the negatives, making it an attractive investment.
| Category | Shares Offered | % of Issue | Share |
|---|---|---|---|
| QIB | 58,12,863 | 49.91% | |
| NII (HNI) | 17,43,859 | 14.97% | |
| Retail | 40,69,004 | 34.94% | |
| Employee | 20,520 | 0.18% |
Premium gain of 19.08% over issue price.
Consistent and strong revenue growth (31.96% CAGR FY24-FY26).
Robust profit growth (40.7% CAGR FY24-FY26).
Healthy EBITDA and PAT margins (EBITDA margin ~22-25%, PAT margin ~11-13%).
Strong return ratios (ROE ~15-16%, ROCE ~17-21%, RoNW ~14-15%).
Significant R&D focus and patent portfolio.
Global presence with 'Truenat' platform.
High overall IPO subscription (70.27x), particularly QIB (186.39x).
Positive GMP (19.08% premium).
Experienced promoter-management team.
Diversified product portfolio (diagnostics, imaging, digital health).
Successful R&D leading to new product launches, aggressive expansion into new geographies, increased adoption of 'Truenat' platform, and favorable government initiatives in healthcare.
Steady growth in the diagnostics market, continued product innovation, stable regulatory environment, and effective management of operational risks.
Intense competitive pressure, adverse regulatory changes, significant supply chain disruptions, failure to manage working capital effectively, and negative impact from the auditor's disclaimer.
Strong GMP (19.08% premium), high overall subscription (70.27x), especially QIB (186.39x), indicates robust demand and a high likelihood of listing gains.
Strong financials, growth trajectory, and positive market sentiment could sustain interest post-listing. However, valuation is not cheap, and some risks exist.
The company operates in a growing sector with strong R&D and a global presence. However, the auditor's disclaimer on internal controls, customer/supplier concentration, and increasing debt are concerns that need to be monitored for long-term sustainability.
Final verdict: Neutral (confidence High).
Positive: Consistent and strong revenue growth (31.96% CAGR FY24-FY26).
Concern: Auditor's disclaimer on internal financial controls for FY23 and FY24.
Listing-gain vs long-term: Apply / Apply.
Concern: High customer concentration (significant revenue from top 10 customers).